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Abstract This study hypothesises that an educational leaflet
about psoriatic arthritis (PsA) will improve psoriasis patients’
attendance for screening for PsA. A random sample of pa-
tients ≥18 years old with a coded diagnosis of psoriasis and
no diagnosis of PsA, rheumatoid arthritis or ankylosing spon-
dylitis were identified from five GP surgeries in Yorkshire,
UK. Patients were randomised 1:1 to receive study informa-
tion alone or with the educational leaflet, with an invitation to
attend for a screening examination by a dermatologist and
rheumatologist. Nine hundred thirty-two invitation packs
were sent to recruit 191 (20.5%) participants. One hundred
sixty-nine (88.5%) had current or previous psoriasis and 17
(10.1%) had previously undiagnosed PsA. The estimated
prevalence of PsAwas 18.1% (95% CI: 16.2, 20.1%).
The response rate was lower than expected and was not
significantly higher when patients received the educational
leaflet (22.8 vs 18.3%, p = 0.08). Response rates varied by
practice (14.7 to 30.6%). However, deprivation scores for
each practice revealed a significant increase in response with
the leaflet for deprivation decile of 3 (p < 0.001) but no sig-
nificant differences in the other practices. An educational leaf-
let about PsA improves attendance for screening in primary
care, but only in those practices with higher levels of socio-
economic deprivation.
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Introduction
Psoriatic arthritis (PsA) manifests clinically in several
ways including arthritis, enthesitis, dactylitis, axial dis-
ease, skin and nail involvement. The majority of people
with this condition have pre-existing psoriasis [1], but
studies have shown that there are many cases of
established PsA which remain unidentified for some
time, despite an established diagnosis of psoriasis [2].
Possible causes of this are patients’ lack of understand-
ing of the link between the skin and arthritis, and the
lack of musculoskeletal expertise in primary care and,
for those referred with their skin problem, treating der-
matologists. It follows that a simple method of screen-
ing for psoriatic arthritis in people with psoriasis would
prevent unnecessary suffering and enable earlier treat-
ment of this potentially disabling disease [3]. Indeed,
recent consensus guidelines from the UK for managing
psoriasis (both the Scottish Intercollegiate Guidelines
Network (SIGN) guidelines for psoriasis and psoriatic
arthritis [4] and the National Institute for Health and
Care Excellence (NICE) guidelines for management of
psoriasis [5]) recommend annual screening for PsA
amongst patients with psoriasis both in primary and
secondary care.
However, the response to screening is not optimal. In
the comparison of three screening tools to detect psori-
atic arthritis in patients with psoriasis (CONTEST)
study, comparing screening questionnaires in secondary
care dermatology clinics, there was only a 70% re-
sponse rate to the questionnaires and of those subse-
quently contacted for a rheumatological assessment,
Laura C. Coates and Laura Savage are the joint first authors.
* Philip S. Helliwell
p.helliwell@leeds.ac.uk
1 Leeds Institute of Rheumatic and Musculoskeletal Medicine,
University of Leeds, 2nd Floor, Chapel Allerton Hospital, Harehills
Lane, Leeds LS7 4SA, UK
2 Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching
Hospitals NHS Trust, Leeds, UK
Clin Rheumatol (2017) 36:719–723
DOI 10.1007/s10067-016-3503-7
only 61% of these attended. This was despite a patient
information sheet explaining why the study was being
conducted.
As noted above, one of the limitations of screening is that
many patients are unaware of the risk of PsA and the impor-
tance of screening for it. In primary care, many patients with
mild psoriasis are not under regular follow-up for psoriasis
with either their GP or a dermatologist, and therefore there is
no opportunity to educate them about PsA.
In other fields in rheumatology, patient education
leaflets have been developed to inform patients of par-
ticular health risks with some evidence of improvement
in patient awareness and attendance for investigation
and treatment [6]. The primary aim of this study is to
test whether educational material explaining the risk of
PsA will improve attendance of patients with psoriasis
for screening.
Materials and methods
Ethical approval was granted by the National Research
Ethics Committee, UK. Patients with psoriasis were
identified from five primary care practices across
Yorkshire with varied socioeconomic backgrounds.
Each practice performed a database search to identify
potential subjects. Patients were eligible for participation
if they were aged 18 years or over, had a diagnostic
label of psoriasis (by read code M161, x506Y, M16Y)
but did not have a coexistent diagnosis of psoriatic ar-
thritis (read code M160), ankylosing spondylitis (read
code N100) or rheumatoid arthritis (read code N40). A
random sample from each practice was taken and infor-
mation about the study was posted to those patients
from November 2013 to November 2014. Patients were
randomised 1:1 to receive the study information alone
or the study information with an educational leaflet
about psoriatic arthritis (Fig. 1).
The educational leaflet was a small folded card with
stylised graphics depicting the common ways in which PsA
can present, including peripheral arthritis, dactylitis, enthesitis
and spinal disease. All patients were asked to return a reply
slip if they were willing to attend one study visit at their gen-
eral practitioner’s (GP) surgery for assessment by a visiting
dermatologist and a visiting rheumatologist. Clinics were held
in the evening to aid attendance. The dermatologist and rheu-
matologist were blind to the intervention.
At the study visit, following informed, written consent,
patients were asked to complete a questionnaire booklet in-
cluding the Psoriasis Epidemiology Screening Tool (PEST)
[7] and CONTEST screening questionnaires [8], PsA quality
of life (PsAQoL) [9], dermatology life quality index (DLQI)
and health assessment questionnaire (HAQ). They were then
reviewed independently by a dermatologist (LS) and a rheu-
matologist (LCC, ARM or PSH). Dermatology assessment
confirmed the presence of psoriasis and assessed severity of
skin and nail involvement. Rheumatology assessment includ-
ed examination of any arthritis, entheseal tenderness and
dactylitis to make a diagnosis of PsAwhere appropriate.
Statistics
To compare the response rates according to the provi-
sion of the educational leaflet, it was assumed that a
20% difference in response rate (50% response without
leaflet, 70% response rate with leaflet) would be of
clinical significance. Given this 20% difference, an al-
pha level of 0.05, and a beta of 0.9, using a two-sided
test, the estimated sample size is 124 per group, 248 in
total. This represents the total number of screening in-
vites that need to be sent out to patients identified by
the practices.
A secondary aim of this study was to validate the
CONTEST screening questionnaire which required a mini-
mum sample size of 191 patients attending for examination.
Therefore, the study aimed to recruit a total of 191 patients to
be examined with a minimum of 248 packs distributed.
Response rates to the leaflet were compared using a chi-
squared test. Analysis was done using IBM’s SPSS Statics
Software.
Results
A total of 932 packs were sent out from the five GP practices
to recruit 191 participants who agreed to attend for assess-
ment. The response rate to the study invitation was lower than
predicted at 20.5%. Of the patients attending for assessment,
169 (88.5%) were found to have current or previous psoriasis.
Using physician diagnosis, 17 (10.1%) were found to have
previously undiagnosed PsA, 90 (53.3%) were found to have
another musculoskeletal complaint and 62 (36.7%) had no
musculoskeletal problems. Using data from the practices and
correcting for misdiagnosis of psoriasis, the estimated preva-
lence of PsAwas 18.1% (95%CI 16.2–20.1%).
Overall, the response rate was lower than predicted and
was not significantly higher when patients received the edu-
cational leaflet (22.8 vs 18.3%, p = 0.088). There was a
marked variation in response rates between the five GP prac-
tices involved (14.7 to 30.6%). When considering each prac-
tice individually, response rates, stratified by leaflet provision,
are shown in Table 1.
Baseline characteristics of the leaflet and no leaflet groups
are shown in Table 2.
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Socioeconomic data of the registered patients at each prac-
tice were obtained from National Statistics on deprivation
with each practice given a decile score (range 1–10 where
level 1 represented the most deprived area and level 10 the
least deprived—Public Health England, National General
Practice Profiles). In our study, one practice had a deprivation
score of 3, one had a score of 7 and the rest had a score of 10.
Analysing the impact of the leaflet on response rates by
deprivation showed that there was a significant increase in
response with the leaflet for the practice with a deprivation
decile of 3 (response rate 30.4 vs 3.7%, p < 0.001), but there
was no significant difference identified in the other practices.
In the practice with the deprivation index of 7, there was a
numerical difference between the response rates (18.7 vs
10.7%) but it did not reach significance. Only 150 packs were
sent out at this practice.
Fig. 1 Educational leaflet sent with study information
Table 1 Response rates by leaflet














A 10 Leaflet 54 29.6 0.044 0.835
No leaflet 54 31.5
B 3 Leaflet 46 30.4 13.21 <0.001
No leaflet 54 3.7
C 10 Leaflet 150 21.3 0.001 0.976
No leaflet 151 21.2
D 10 Leaflet 136 21.3 0.109 0.741
No leaflet 137 19.7
E 7 Leaflet 75 18.7 1.92 0.166
No leaflet 75 10.7
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Discussion
This study did not identify a significant improvement in
attendance for PsA screening in the entire cohort but
within the practice with the lowest deprivation index;
there was a marked difference in the proportion attend-
ing for screening. In the practice with the deprivation
index of 7, there was a suggestion of a difference but it
did not reach significance (18.7 vs 10.7%, p = 0.166).
Given that there were only 150 packs sent out at this
practice, this may represent a type II error.
The response rate was lower than predicted at around
20%. This is significantly lower than response rates in
previous secondary care settings, but this was an unso-
licited postal invitation, albeit from their primary care
provider, rather than an invitation from their treating
dermatologist, if the patient had a secondary care pro-
vider. This may have introduced a type II error as the
sample size originally assumed a 50% response rate.
However, in the overall sample, the difference in
response was not large enough to suggest utility of the
leaflet for general use. The least deprived practices (A,
C and D) did not show any difference in response with
the leaflet and also showed the higher response rates of
20–30%. There was a trend towards a difference in
practice E with a deprivation index of 7 and a strong
effect with the leaflet in practice B which had the low-
est deprivation index of 3. This suggests that the leaflet
may play a useful educational role in low socioeconom-
ic areas. In such areas, attendance for health screening
is traditionally poor, and giving this information in an
easy to read, cartoon format at ‘opportune’ moments,
such as consultations, may improve identification of
psoriatic arthritis in patients with psoriasis. The re-
sponse rate without the leaflet was only 3% but in-
creased with the leaflet to 30%, similar to maximum
response rate at any of the practices.
The assumption that screening to identify undiagnosed
cases of PsA is worthwhile has not been formally assessed
but is based on observational studies in which shorter
Table 2 Baseline characteristics
by leaflet No leaflet (n = 86) Leaflet (n = 105) p
Age 59 (55.62) 58 (55.61) 0.82
Sex (male) 56% 45% 0.15
Ps duration (years) 27 (23.31) 27 (24.31) 0.96
Diagnosis 0.35
PsA 8 (9%) 9 (9%)
Not MSK 36 (42%) 34 (32%)
OA/mechanical 32 (38%) 51 (48%)
Other MSK 10 (11%) 11 (11%)
PSO 0.37
Current 69 (80%) 75 (71%)
Previous 9 (11%) 16 (15%)
Not PSO 8 (9%) 14 (13%)
PSO symptoms on the day 0.77
No 36 (42%) 47 (45%)
Yes 50 (58%) 58 (55%)
PASI score 4.0 (2.9, 5.1) 2.3 (1.6, 3.0) 0.01
mNAPSI score 6.6 (4.2, 9.0) 5.1 (3.2, 7.0) 0.34
Enthesis score 1.1 (0.5, 1.7) 1.8 (0.9, 2.6) 0.24
Dactylitis present 1 (1%) 0 0.27
Tender joint count 1.7 (1.0, 2.4) 3.5 (1.7, 5.3) 0.09
Swollen joint count 0.4 (0.1, 0.6) 0.8 (0.3, 1.3) 0.14
HAQ 0.2 (0.1, 0.3) 0.3 (0.2, 0.6) 0.11
PsAQoL 3.3 (2.2, 4.4) 4.2 (3.0, 5.4) 0.63
DLQI 3.6 (2.7, 4.5) 3.5 (2.6, 4.4) 0.87
Contest 3.7 (3.0, 4.4) 3.7 (3.0, 4.5) 0.44
Contest joints reported (mean) 4.8 (3.8, 5.9) 5.8 (4.7, 6.8) 0.36
PsA psoriatic arthritis,MSK musculoskeletal, PSO psoriasis, PASI psoriasis area and severity index, mNAPSI the
modified nail psoriasis severity index, HAQ health assessment questionnaire, PsAQoL the psoriatic arthritis
quality of life measure, DLQI dermatology quality of life index
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disease latency at diagnosis is associated with better out-
comes [10–12]. Although the National Institute for Health
and Clinical Effectiveness (NICE) has recommended an-
nual screening for PsA [5], anecdotal evidence suggests
this has not been widely adopted (personal communica-
tion from the Psoriasis Association). Clearly both patients
and health providers in both primary and secondary care
need more education about the risks associated with un-
diagnosed (and by implication untreated) PsA. The matter
is further complicated by the fact that many patients with
relatively mild psoriasis do not regularly visit a health
professional in either primary or secondary care, perhaps
being happy to self-medicate this problem. The lack of
association between the severity of the skin disease and
the severity of the musculoskeletal disease does not mean
that mild psoriasis means mild PsA.
The main strength of this study is that it was conducted in a
real life, community-based, screening program using a vali-
dated screening questionnaire. The study was also able to
access a diverse range of communities varying widely in so-
cioeconomic status. Further, all patients had a full examination
by a rheumatologist and a dermatologist, in the primary care
setting. Aweakness was the poor overall response to invitation
for screening. As this was far below the expected response
rate, it is likely that this study was underpowered, as the sam-
ple size was based on a much higher response rate (50/70%
predicted for ‘no leaflet’/‘leaflet’ against 18/23% actual study
figures). The study is also not able to explain why there was a
higher response to screening with the leaflet in the poorer
socioeconomic areas but may reflect the educational value of
the leaflet in this less well-educated population.
In conclusion, screening for musculoskeletal disease in
people with psoriasis is important in order to reduce long-
term morbidity. It is likely that education of patients and phy-
sicians is likely to have the most impact: the addition of a
simple leaflet may help, particularly if given in person by a
health care practitioner. The leaflet as an educational tool is
likely to be of more benefit in lower socioeconomic areas.
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